Article
Limiting dilution analysis: from frequencies to cellular interactions.
Dept of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Immunology Today
02/2000;
21(1):15-8.
DOI:10.1016/S0167-5699(99)01561-3
pp.15-8
Source: PubMed
-
Citations (0)
- Cited In (7)
-
Article: Limiting Dilution Analysis of Interleukin-2 Producing Helper T-cell Frequencies as a Tool in Allogeneic Hematopoietic Cell Transplantation
[show abstract] [hide abstract]
ABSTRACT: Background. A reliable in vitro test that estimates the level of ongoing alloreactivity would be valuable in allogeneic hematopoietic cell transplantation (HCT) as a help to guide clinical interventions such as donor lymphocyte infusions and changes in the immunosuppression. In the present study, the use of limiting dilution analysis of interleukin-2 (IL-2) producing helper T lymphocyte frequencies (HTL assay) as a way to quantify alloreactivity following HCT was investigated. Methods. Serial HTL assays were performed following allogeneic HCT with myeloablative or nonmyeloablative con-ditioning in 26 patients with hematologic malignancies. Results. Deviations from single-hit kinetics were frequently observed in the HTL assays and a nonlinear model was therefore used for analysis. The results of this analysis suggested the presence of an inhibitory cell population. Inhibition was observed in the majority of patients and was not restricted to a specific transplant regimen. Inhibition occurred more often with high frequencies of IL-2 producing cells, indicating a physiological role of the putative inhibitory cell population in the regulation of an immune response. Higher frequencies of IL-2 producing cells were observed in patients with acute graft-versus-host disease grades II-IV than in patients with grades 0-I (P 0.046), indicating that the degree of ongoing alloreactivity is indeed quantified by the HTL assay. Conclusions. We find that the HTL assay may yield interesting insight into regulation of immune responses following allogeneic HCT, but because of the complexity of the results obtained, its use as a routine procedure to guide immu-nosuppression cannot be recommended. T he curative effect of allogeneic hematopoietic cell trans-plantation (HCT) with nonmyeloablative conditioning relies on the ability of the transplanted donor cells to exert a graft-versus-tumor effect. The donor cells can also cause graft-versus-host disease (GVHD) and careful control of the immunosuppression is important for the treatment results. The ability to monitor alloreactivity by the use of a reliable in vitro test is therefore desirable in clinical transplantation (1). Limiting dilution analysis (LDA) of helper T-lymphocyte precursors (HTLp) has been used to detect frequencies of alloreactive interleukin-2 (IL-2) producing donor T cells di-rected against major or minor histocompatibility antigens of the recipient. Clinically useful associations between HTLp frequencies pretransplant and the subsequent development of relapse, acute, or chronic GVHD have been reported by several groups including our own (2–9). There are also stud-ies where these associations have not been found (10 –12), and it is uncertain whether information obtained from stud-ies of recipients of bone marrow can be applied to recipients of peripheral blood stem cells (PBSC) and nonmyeloablative or reduced-intensity conditioning regimens (13). The HTLp assay has been used posttransplant in a few studies, and it has been suggested that a high IL-2 producing cell frequency in the graft-versus-host (GVH) direction was related to or even preceded acute or chronic GVHD (14,15). Similarly, rejection of the graft has recently been associated with high antidonor IL-2 producing T cell frequencies following nonmyeloabla-tive bone marrow transplantation (16). The purpose of the present study was to investigate whether LDA of in vivo primed IL-2 producing helper T lym-phocytes (HTL assay) could be used to monitor alloreactivityTransplantation 01/2005; 80:573-581. · 4.00 Impact Factor -
Article: Immunologic monitoring.
[show abstract] [hide abstract]
ABSTRACT: The development of reliable in vitro assays that could allow the quantitation and characterization of anti-donor alloimmune responses has always been a goal in clinical transplantation, both to predict presensitization to the transplanted tissue and to be able to identify rejection without resorting to more invasive tests. With recent development in our understanding of transplantation biology and therapeutics, there is a real expectation that these tests may be used to identify tolerance as much as to predict rejection. The traditional limiting dilution assays still have a contribution to make and are being complemented by an array of tools, such as ELISpot, flow cytometry-based techniques, and microarray analysis. The assays that have been informative, to date, are discussed in this review. This information will lead, at least, to a better understanding of how and when the rejection process occurs. More interestingly, the objective is to apply this information to evaluate tolerance-inducing strategies or to identify patients that have become tolerant to their graft and can be weaned of immunosuppression. Of course sensitive, accurate and specific immunologic monitoring has applications well beyond the field of transplantation.Immunological Reviews 01/2004; 196:247-64. · 11.15 Impact Factor -
Article: Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome.
[show abstract] [hide abstract]
ABSTRACT: The authors' previous studies with 2 different adult patient populations demonstrated a correlation between indirect allorecognition of mismatched donor HLA Class I- and Class II-derived peptides and the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation. The aim of this study was to determine whether a parallel allorecognition of mismatched donor HLA Class I- and Class II-derived peptides occurs after lung transplantation and to determine its correlation with the development of BOS after lung transplantation in a group of pediatric patients. Peripheral blood mononuclear cells from 7 BOS-positive and 6 BOS-negative pediatric lung transplant recipients (age, 11.5 +/- 4.4 years) were cultured in the presence of synthetic peptides corresponding to the alpha-chain hypervariable regions of a mismatched donor HLA Class I molecule and the beta-chain hypervariable region of a mismatched donor HLA-DR molecule. The frequencies of HLA Class I and Class II alloreactive T cells were determined using limiting dilution analysis. A significant increase (p = 0.025) in HLA Class I-alloreactive T cells was observed in BOS-positive patients (7.1 x 10(-5) +/- 4.3 x 10(-5)) compared with BOS-negative patients (2.1 x 10(-5) +/- 1.8 x 10(-6)). In addition, a significant increase (p = 0.033) in HLA Class II-alloreactive T cells also was observed in BOS-positive patients (9.6 x 10(-5) +/- 7.9 x 10(-5)) compared with BOS-negative patients (1.3 x 10(-5) +/- 2.1 x 10(-6)). This study indicates that a parallel CD4+ T-cell alloreactivity to both donor HLA Class I and Class II molecules may play a role in the pathogenesis of BOS both in adult and pediatric lung transplant recipients.The Journal of Heart and Lung Transplantation 02/2003; 22(1):35-43. · 4.33 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.